Morgan Stanley’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-675
| Closed | -$2.54K | – | 8216 |
|
|
2024
Q3 | $2.54K | Sell |
675
-717
| -52% | -$4.12K | ﹤0.01% | 7083 |
|
|
2024
Q2 | $13.3K | Buy |
1,392
+407
| +41% | +$13.7K | ﹤0.01% | 6579 |
|
|
2024
Q1 | $74.5K | Sell |
985
-111
| -10% | -$14.6K | ﹤0.01% | 6092 |
|
|
2023
Q4 | $195K | Buy |
1,096
+966
| +743% | +$475K | ﹤0.01% | 5958 |
|
|
2023
Q3 | $91.5K | Buy |
130
+31
| +31% | +$133K | ﹤0.01% | 5933 |
|
|
2023
Q2 | $455K | Buy |
99
+8
| +9% | +$27.8K | ﹤0.01% | 5261 |
|
|
2023
Q1 | $242K | Hold |
91
| – | – | ﹤0.01% | 5624 |
|
|
2022
Q4 | $239K | Buy |
91
+7
| +8% | +$24.4K | ﹤0.01% | 5590 |
|
|
2022
Q3 | $331K | Sell |
84
-15
| -15% | -$59K | ﹤0.01% | 5477 |
|
|
2022
Q2 | $258K | Buy |
99
+3
| +3% | +$7.81K | ﹤0.01% | 5770 |
|
|
2022
Q1 | $309K | Buy |
96
+7
| +8% | +$30.1K | ﹤0.01% | 5677 |
|
|
2021
Q4 | $555K | Buy |
89
+54
| +154% | +$415K | ﹤0.01% | 5482 |
|
|
2021
Q3 | $325K | Sell |
35
-216
| -86% | -$1.86M | ﹤0.01% | 5740 |
|
|
2021
Q2 | $2.54M | Buy |
251
+249
| +12,450% | +$4.09M | ﹤0.01% | 4453 |
|
|
2021
Q1 | $43K | Buy |
2
+1
| +100% | +$11.7K | ﹤0.01% | 6418 |
|
|
2020
Q4 | $6K | Sell |
1
-2
| -67% | -$7.85K | ﹤0.01% | 6752 |
|
|
2020
Q3 | $9K | Hold |
3
| – | – | ﹤0.01% | 6313 |
|
|
2020
Q2 | $10K | Buy |
+3
| New | +$9.96K | ﹤0.01% | 6164 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6744 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6770 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6836 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6618 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6722 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6677 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6475 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6529 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6250 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6470 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6331 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6317 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6159 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6269 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6135 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6177 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 5907 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6444 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6332 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6233 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 5888 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 5681 |
|
Other funds holding SEEL
Morgan Stanley's SEEL Position: Q4 2024 in Review
Morgan Stanley sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 675 shares — an estimated $2.54K sold.
Morgan Stanley first reported a position in SEEL in Q2 2020 and held it in 18 quarters. The position peaked at $2.54M in Q2 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- Morgan Stanley reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Morgan Stanley sold 675 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $2.54K.
- Morgan Stanley first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- Morgan Stanley's Seelos Therapeutics, Inc. Common Stock position peaked at $2.54M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.